| 30.61 Real-Time Quote |  -0.59 / -1.89%Today’s Change | 15.02 Today|||52-Week Range 34.30 | +65.28% Year-to-Date |
| Biogen Delays EU Launch of Tecfidera - Analyst Blog May 31 / Zacks.com | Amgen-Astellas Collaborate - Analyst Blog May 29 / Zacks.com |
| Encouraging Data from Alkermes - Analyst Blog May 29 / Zacks.com |
| Previous close | 31.20 |
| Today’s open | 31.62 |
| Day’s range | 30.75 - 31.62 |
| Volume | 301,264 |
| Average volume (3 months) | 1,413,569 |
| Market cap | $4.2B |
| Dividend yield | -- |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -17.63% |
| Earnings growth (next 5 years) | +27.83% |
| Revenue growth (last year) | +47.59% |
| P/E ratio | NM |
| Price/Sales | 5.42 |
| Price/Book | 4.38 |
| Today’s change | Today’s % change | |
|---|---|---|
| ENDPEndo Health Solution... | +0.79 | +2.11% |
| SGENSeattle Genetics Inc | +0.53 | +1.57% |
| JAZZJazz Pharmaceuticals... | +0.21 | +0.31% |
| IDXXIDEXX Laboratories I... | -0.20 | -0.24% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | $0.30 |
| Annual revenue (last year) | $575.5M |
| Annual profit (last year) | $25.0M |
| Net profit margin | 4.34% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Richard F. Pops |
President Shane Cooke |
Corporate headquarters Dublin, Dublin |
.
